Paolo Maria Comoglio
#104,943
Most Influential Person Now
Researcher
Paolo Maria Comoglio's AcademicInfluence.com Rankings
Paolo Maria Comoglioengineering Degrees
Engineering
#2855
World Rank
#3844
Historical Rank
Bioengineering
#20
World Rank
#22
Historical Rank
Biomedical Engineering
#99
World Rank
#100
Historical Rank
Applied Physics
#423
World Rank
#440
Historical Rank
Download Badge
Engineering
Paolo Maria Comoglio's Degrees
- PhD Biomedical Engineering Polytechnic University of Turin
- Masters Biomedical Engineering Polytechnic University of Turin
- Bachelors Biomedical Engineering Polytechnic University of Turin
Why Is Paolo Maria Comoglio Influential?
(Suggest an Edit or Addition)Paolo Maria Comoglio's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth (1992) (1350)
- Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. (2003) (1296)
- Plexins Are a Large Family of Receptors for Transmembrane, Secreted, and GPI-Anchored Semaphorins in Vertebrates (1999) (1098)
- MET signalling: principles and functions in development, organ regeneration and cancer (2010) (1072)
- A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family (1994) (1010)
- Drug development of MET inhibitors: targeting oncogene addiction and expedience (2008) (806)
- A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. (2011) (794)
- Scatter-factor and semaphorin receptors: cell signalling for invasive growth (2002) (766)
- Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. (1991) (710)
- Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. (2016) (639)
- Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. (1992) (587)
- Regulation of scatter factor/hepatocyte growth factor responses by Ras, Rac, and Rho in MDCK cells (1995) (578)
- Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. (2013) (560)
- Induction of epithelial tubules by growth factor HGF depends on the STAT pathway (1998) (532)
- Invasive growth: a MET-driven genetic programme for cancer and stem cells (2006) (503)
- Expression of the Met/HGF receptor in normal and neoplastic human tissues. (1991) (496)
- Tyrosine kinase receptor indistinguishable from the c-met protein (1989) (474)
- The endophilin–CIN85–Cbl complex mediates ligand-dependent downregulation of c-Met (2002) (467)
- Plexin A Is a Neuronal Semaphorin Receptor that Controls Axon Guidance (1998) (462)
- The Semaphorin 4D receptor controls invasive growth by coupling with Met (2002) (454)
- Rous sarcoma virus-transformed fibroblasts adhere primarily at discrete protrusions of the ventral membrane called podosomes. (1985) (446)
- A Signaling Adapter Function for α6β4 Integrin in the Control of HGF-Dependent Invasive Growth (2001) (408)
- Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. (2005) (376)
- Signalling by semaphorin receptors: cell guidance and beyond. (2000) (360)
- Ezrin Is an Effector of Hepatocyte Growth Factor–mediated Migration and Morphogenesis in Epithelial Cells (1997) (331)
- Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas (2000) (327)
- The receptor encoded by the human C‐MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors (1991) (313)
- RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. (1994) (313)
- Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. (2016) (311)
- Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. (2011) (308)
- The Met tyrosine kinase receptor in development and cancer (2008) (305)
- Uncoupling of Grb2 from the Met Receptor In Vivo Reveals Complex Roles in Muscle Development (1996) (303)
- Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. (2004) (301)
- The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. (1995) (298)
- Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. (1995) (274)
- The MET receptor tyrosine kinase in invasion and metastasis (2007) (273)
- Biological Activation of pro-HGF (Hepatocyte Growth Factor) by Urokinase Is Controlled by a Stoichiometric Reaction (*) (1995) (261)
- Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages (2008) (260)
- The MET oncogene drives a genetic programme linking cancer to haemostasis (2005) (254)
- Cancer therapy: can the challenge be MET? (2005) (252)
- Interactions between growth factor receptors and adhesion molecules: breaking the rules. (2003) (250)
- Sema4D induces angiogenesis through Met recruitment by Plexin B1. (2005) (239)
- The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase. (1991) (229)
- Invasive growth: from development to metastasis. (2002) (227)
- Overexpression of the MET/HGF receptor in ovarian cancer (1994) (226)
- A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis. (1992) (225)
- Biosynthesis of the protein encoded by the c-met proto-oncogene. (1989) (218)
- Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy (2018) (216)
- Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor). (1994) (214)
- Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. (1996) (213)
- Overexpression of the RON gene in human breast carcinoma (1998) (204)
- Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression. (1993) (203)
- Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. (1996) (201)
- Egf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB‐2 protein in the mammary tumor cell line SK‐BR‐3. (1988) (199)
- Hepatocyte growth factor/scatter factor stimulates the Ras-guanine nucleotide exchanger. (1993) (193)
- A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. (2001) (192)
- Interplay between scatter factor receptors and B plexins controls invasive growth (2004) (189)
- MicroRNAs impair MET-mediated invasive growth. (2008) (183)
- Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. (1998) (183)
- A novel recognition motif for phosphatidylinositol 3-kinase binding mediates its association with the hepatocyte growth factor/scatter factor receptor (1993) (182)
- Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas (2012) (181)
- Cross-talk between the proto-oncogenes Met and Ron (2000) (180)
- A family of transmembrane proteins with homology to the MET-hepatocyte growth factor receptor. (1996) (178)
- The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation (1991) (177)
- A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype (1996) (175)
- Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. (2006) (175)
- The Transmembrane Protein Off-Track Associates with Plexins and Functions Downstream of Semaphorin Signaling during Axon Guidance (2001) (172)
- A Natural Hepatocyte Growth Factor/Scatter Factor Autocrine Loop in Myoblast Cells and the Effect of the Constitutive Met Kinase Activation on Myogenic Differentiation (1997) (171)
- Sustained recruitment of phospholipase C-γ to Gab1 is required for HGF-induced branching tubulogenesis (2000) (169)
- Transgenic expression in the liver of truncated Met blocks apoptosis and permits immortalization of hepatocytes (1997) (168)
- MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. (2010) (166)
- c-met is amplified but not mutated in a cell line with an activated met tyrosine kinase. (1991) (165)
- Hepatocyte growth factor (HGF) receptor expression is inducible and is part of the delayed-early response to HGF. (1994) (165)
- Specific Uncoupling of GRB2 from the Met Receptor (1996) (164)
- Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies. (2018) (164)
- Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. (2010) (162)
- C-terminal truncated forms of Met, the hepatocyte growth factor receptor (1991) (160)
- HGF: a multifunctional growth factor controlling cell scattering. (1999) (159)
- To move or not to move? (2004) (159)
- Plexin‐B3 is a functional receptor for semaphorin 5A (2004) (155)
- Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells (1997) (152)
- Phosphorylation of serine 985 negatively regulates the hepatocyte growth factor receptor kinase. (1994) (148)
- Overexpression of the met/HGF receptor in renal cell carcinomas (1996) (147)
- Monoclonal antibodies against murine gamma interferon. (1984) (144)
- Hepatocyte growth factor and its receptor are required for malaria infection (2003) (141)
- The tyrosine kinase receptors Ron and Sea control "scattering" and morphogenesis of liver progenitor cells in vitro. (1996) (141)
- Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists (1999) (140)
- A High Affinity Hepatocyte Growth Factor-binding Site in the Immunoglobulin-like Region of Met* (2008) (133)
- Gab1 coupling to the HGF/Met receptor multifunctional docking site requires binding of Grb2 and correlates with the transforming potential (1997) (132)
- Hepatocyte growth factor induces proliferation and differentiation of multipotent and erythroid hemopoietic progenitors (1994) (132)
- ROR1 is a pseudokinase that is crucial for MET-driven tumorigenesis (2011) (132)
- β4 integrin activates a Shp2–Src signaling pathway that sustains HGF-induced anchorage-independent growth (2006) (131)
- The MET oncogene is a functional marker of a glioblastoma stem cell subtype. (2012) (130)
- Wild-type p53 controls cell motility and invasion by dual regulation of MET expression (2011) (129)
- Scatter factors and invasive growth. (2001) (128)
- Proteolytic processing converts the repelling signal Sema3E into an inducer of invasive growth and lung metastasis. (2005) (127)
- MiR-1 Downregulation Cooperates with MACC1 in Promoting MET Overexpression in Human Colon Cancer (2011) (127)
- Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas. (1996) (126)
- MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. (2014) (126)
- ERK: A Key Player in the Pathophysiology of Cardiac Hypertrophy (2019) (125)
- A positive feedback loop between hepatocyte growth factor receptor and β-catenin sustains colorectal cancer cell invasive growth (2007) (125)
- Targeting of the SF/HGF receptor to the basolateral domain of polarized epithelial cells (1994) (125)
- Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. (2002) (124)
- Genetic and Expression Analysis of MET, MACC1, and HGF in Metastatic Colorectal Cancer: Response to Met Inhibition in Patient Xenografts and Pathologic Correlations (2011) (124)
- The Met pathway: master switch and drug target in cancer progression (2006) (122)
- HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity (2000) (122)
- The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. (2003) (122)
- Identification of the major autophosphorylation site of the Met/hepatocyte growth factor receptor tyrosine kinase. (1991) (120)
- MET overexpression turns human primary osteoblasts into osteosarcomas. (2006) (119)
- Reactive Oxygen Species Mediate Met Receptor Transactivation by G Protein-coupled Receptors and the Epidermal Growth Factor Receptor in Human Carcinoma Cells* (2004) (118)
- Cell surface molecules and fibronectin-mediated cell adhesion: effect of proteolytic digestion of membrane proteins (1982) (116)
- Detection of phosphotyrosine‐containing proteins in the detergent‐insoluble fraction of RSV‐transformed fibroblasts by azobenzene phosphonate antibodies. (1984) (116)
- Fibronectin-plasma membrane interaction in the adhesion of hemopoietic cells (1986) (114)
- To move or not to move? Semaphorin signalling in cell migration. (2004) (112)
- Apoptosis Enhancement by the HIV-1 Nef Protein1 (2001) (111)
- Control of invasive growth by hepatocyte growth factor (HGF) and related scatter factors. (1997) (109)
- The proto-oncogene RON is involved in development of epithelial, bone and neuro-endocrine tissues. (1995) (107)
- Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition (2010) (107)
- The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment (2008) (103)
- Overexpression of stromelysin-3, BM-40/SPARC, and MET genes in human esophageal carcinoma: implications for prognosis. (1998) (102)
- An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. (2004) (101)
- p190 Rho-GTPase activating protein associates with plexins and it is required for semaphorin signalling (2005) (100)
- Truncated RON Tyrosine Kinase Drives Tumor Cell Progression and Abrogates Cell-Cell Adhesion Through E-Cadherin Transcriptional Repression (2004) (99)
- IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies (2015) (98)
- Cancer: the matrix is now in control (2005) (97)
- Novel mutation in the ATP‐binding site of the MET oncogene tyrosine kinase in a HPRCC family (1999) (96)
- Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth. (1998) (96)
- Pathway specificity for Met signalling (2001) (96)
- Src‐mediated activation of α‐diacylglycerol kinase is required for hepatocyte growth factor‐induced cell motility (2000) (95)
- Cleavage of a 135 kD cell surface glycoprotein correlates with loss of fibroblast adhesion to fibronectin. (1985) (95)
- Angiogenesis induced in vivo by hepatocyte growth factor is mediated by platelet-activating factor synthesis from macrophages. (1997) (95)
- The hyaluronate receptor is identical to a glycoprotein of Mr 85,000 (gp85) as shown by a monoclonal antibody that interferes with binding activity. (1987) (94)
- Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30 (2008) (94)
- Only a subset of Met-activated pathways are required to sustain oncogene addiction. (2009) (94)
- Constitutive activation of the RON gene promotes invasive growth but not transformation (1996) (94)
- Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells. (1993) (93)
- EXPRESSION OF Met PROTEIN IN THYROID TUMOURS (1996) (90)
- Magic-Factor 1, a Partial Agonist of Met, Induces Muscle Hypertrophy by Protecting Myogenic Progenitors from Apoptosis (2008) (89)
- Different point mutations in the met oncogene elicit distinct biological properties (2000) (87)
- Interactions between scatter factors and their receptors: hints for therapeutic applications (1998) (86)
- Negative/low expression of the Met/hepatocyte growth factor receptor identifies papillary thyroid carcinomas with high risk of distant metastases. (1997) (86)
- Beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis. (2005) (84)
- Functional Regulation of Semaphorin Receptors by Proprotein Convertases* (2003) (84)
- Staging of head and neck squamous cell carcinoma using the MET oncogene product as marker of tumor cells in lymph node metastases (2000) (84)
- Expression of Met/hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors. (1996) (82)
- Monovalency Unleashes the Full Therapeutic Potential of the DN-30 Anti-Met Antibody* (2010) (81)
- Hepatocyte Growth Factor Is a Regulator of Monocyte-Macrophage Function1 (2001) (80)
- Osteopontin is an autocrine mediator of hepatocyte growth factor-induced invasive growth. (2001) (80)
- Plexin-B1 plays a redundant role during mouse development and in tumour angiogenesis (2007) (80)
- In vivo activation of met tyrosine kinase by heterodimeric hepatocyte growth factor molecule promotes angiogenesis. (1995) (80)
- Activation of RAS family members confers resistance to ROS1 targeting drugs (2014) (80)
- Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis (1999) (79)
- Immunohistochemistry with antibodies to hepatocyte growth factor and its receptor protein (c-MET) in human brain tissues (1994) (79)
- Overexpression of the C-MET/HGF receptor in human thyroid carcinomas derived from the follicular epithelium (1995) (78)
- TGFalpha expression impairs Trastuzumab-induced HER2 downregulation. (2005) (77)
- Oncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamics. (2013) (77)
- The HGF receptor family: unconventional signal transducers for invasive cell growth (1996) (76)
- A cell surface integral membrane glycoprotein of 85,000 mol wt (gp85) associated with triton X-100-insoluble cell skeleton (1984) (76)
- Expression of hepatocyte growth factor (HGF) and its receptor (MET) in medullary carcinoma of the thyroid (2000) (76)
- The Met oncogene and basal-like breast cancer: another culprit to watch out for? (2010) (74)
- A 135,000 molecular weight plasma membrane glycoprotein involved in fibronectin-mediated cell adhesion. Immunofluorescence localization in normal and RSV-transformed fibroblasts. (1986) (73)
- p145, a protein with associated tyrosine kinase activity in a human gastric carcinoma cell line (1988) (73)
- S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab (2013) (72)
- Selective expression of the Met/HGF receptor in human central nervous system microglia. (1993) (72)
- Karyotypic analysis of gastric carcinoma cell lines carrying an amplified c-met oncogene. (1992) (69)
- Autophosphorylation promotes complex formation of recombinant hepatocyte growth factor receptor with cytoplasmic effectors containing SH2 domains. (1992) (69)
- Genetic link between cancer and thrombosis. (2009) (69)
- A gene trap vector system for identifying transcriptionally responsive genes (2001) (68)
- A Disintegrin and Metalloproteinase-10 (ADAM-10) Mediates DN30 Antibody-induced Shedding of the Met Surface Receptor* (2010) (67)
- Ron kinase transphosphorylation sustains MET oncogene addiction. (2011) (67)
- MET inhibition overcomes radiation resistance of glioblastoma stem‐like cells (2016) (66)
- Defective posttranslational processing activates the tyrosine kinase encoded by the MET proto-oncogene (hepatocyte growth factor receptor) (1991) (65)
- TGFα expression impairs Trastuzumab-induced HER2 downregulation (2005) (65)
- Agonist antibodies activating the Met receptor protect cardiomyoblasts from cobalt chloride-induced apoptosis and autophagy (2014) (65)
- Structural and functional domains critical for constitutive activation of the HGF-receptor (Met). (1994) (65)
- Phosphotyrosine antibodies identify the p210c-abl tyrosine kinase and proteins phosphorylated on tyrosine in human chronic myelogenous leukemia cells (1986) (64)
- MET mutations in cancers of unknown primary origin (CUPs) (2011) (64)
- A Peptide Representing the Carboxyl-terminal Tail of the Met Receptor Inhibits Kinase Activity and Invasive Growth* (1999) (64)
- Plasminogen-related growth factor and semaphorin receptors: a gene superfamily controlling invasive growth. (1999) (63)
- Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET (1999) (62)
- Chemotaxis of 3T3 and SV3T3 cells to fibronectin is mediated through the cell-attachment site in fibronectin and a fibronectin cell surface receptor (1987) (62)
- The Slit/Robo system suppresses hepatocyte growth factor-dependent invasion and morphogenesis. (2008) (62)
- Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene. (2001) (61)
- Negative Feedback Regulation of Met-Dependent Invasive Growth by Notch (2005) (61)
- The MET oncogene in glioblastoma stem cells: implications as a diagnostic marker and a therapeutic target. (2013) (61)
- Protein kinase-c activation inhibits tyrosine phosphorylation of the c-met protein. (1990) (60)
- Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial. (2015) (60)
- Prevention of hypoxia by myoglobin expression in human tumor cells promotes differentiation and inhibits metastasis. (2009) (60)
- Tyrosine kinase signal specificity: lessons from the HGF receptor. (2003) (59)
- Plexins, Semaphorins, and Scatter Factor Receptors: A Common Root for Cell Guidance Signals? (1999) (59)
- Molecular characteristics of HGF-SF and its role in cell motility and invasion. (1993) (58)
- Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs. (2014) (57)
- The HIV-1 Nef Protein Interferes with Phosphatidylinositol 3-Kinase Activation 1 (*) (1996) (56)
- Receptor for bombesin with associated tyrosine kinase activity. (1986) (56)
- The Tetraspanin CD151 Is Required for Met-dependent Signaling and Tumor Cell Growth* (2010) (55)
- Regulation of the urokinase-type plasminogen activator gene by the oncogene Tpr-Met involves GRB2 (1997) (54)
- Identification of functional domains in the hepatocyte growth factor and its receptor by molecular engineering. (1994) (52)
- Progression of familial adenomatous polyposis (FAP) colonic cells after transfer of the src or polyoma middle T oncogenes: cooperation between src and HGF/Met in invasion. (1997) (51)
- Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10 (2011) (50)
- Two dimensional distribution of concanavalin‐A receptor molecules on fibroblast and lymphocyte plasma membranes (1972) (49)
- Invasive growth: a genetic program. (2004) (49)
- Intracellular calcium regulates the tyrosine kinase receptor encoded by the MET oncogene. (1991) (48)
- Hepatocyte growth factor and its receptor, the tyrosine kinase encoded by the c-MET proto-oncogene. (1994) (48)
- Targeting the MET oncogene in cancer and metastases (2010) (47)
- CAR-3, a monoclonal antibody-defined antigen expressed on human carcinomas. (1985) (47)
- Overexpression of c‐met protooncogene product and raised Ki67 index in hepatocellular carcinomas with respect to benign liver conditions (1995) (47)
- Expression of Met protein and urokinase‐type plasminogen activator receptor (uPA‐R) in papillary carcinoma of the thyroid (1998) (47)
- Hepatocyte Growth Factor Sensitizes Human Ovarian Carcinoma Cell Lines to Paclitaxel and Cisplatin (2004) (46)
- A functional role for hemostasis in early cancer development. (2005) (46)
- Control of invasive growth by the HGF receptor family (1997) (45)
- Inhibition of Src Impairs the Growth of Met-Addicted Gastric Tumors (2010) (45)
- The hepatocyte growth factor and its receptor (1993) (45)
- Kinetics and regulation of the tyrosine phosphorylation of epidermal growth factor receptor in intact A431 cells (1988) (45)
- Genetic Evolution of Glioblastoma Stem‐Like Cells From Primary to Recurrent Tumor (2017) (45)
- p38 MAPK turns hepatocyte growth factor to a death signal that commits ovarian cancer cells to chemotherapy‐induced apoptosis (2006) (44)
- Detection of MET oncogene/hepatocyte growth factor receptor in lymph node metastases from head and neck squamous cell carcinomas. (1997) (43)
- Ligand-independent tyrosine phosphorylation of EGF receptor and the erbB-2/neu proto-oncogene product is induced by hyperosmotic shock. (1989) (43)
- Vanadate‐treated baby hamster kidney fibroblasts show cytoskeleton and adhesion patterns similar to their rous sarcoma virus‐transformed counterparts (1988) (43)
- Mutations in the met Oncogene Unveil a “Dual Switch” Mechanism Controlling Tyrosine Kinase Activity* (2003) (42)
- TNF‐α promotes invasive growth through the MET signaling pathway (2015) (42)
- Generation of a truncated hepatocyte growth factor receptor in the endoplasmic reticulum. (1994) (41)
- Molecular profiling of the “plexinome” in melanoma and pancreatic cancer (2009) (41)
- Hepatocyte growth factor (HGF) stimulates tumour invasiveness in papillary carcinoma of the thyroid (1999) (40)
- Bombesin stimulation of c-fos and c-myc gene expression in cultures of Swiss 3T3 cells. (1986) (40)
- A protein tyrosine phosphatase activity associated with the hepatocyte growth factor/scatter factor receptor. (1993) (39)
- In vivo phosphorylation and dephosphorylation of the platelet-derived growth factor receptor studied by immunoblot analysis with phosphotyrosine antibodies. (1986) (39)
- Targeting the oncogenic Met receptor by antibodies and gene therapy (2014) (39)
- "Active" cancer immunotherapy by anti-Met antibody gene transfer. (2008) (38)
- Over‐expression of hepatocyte growth factor in human Kaposi's sarcoma (1996) (38)
- The ROR1 pseudokinase diversifies signaling outputs in MET‐addicted cancer cells (2014) (37)
- MET, a driver of invasive growth and cancer clonal evolution under therapeutic pressure. (2014) (36)
- Protein tyrosine phosphatase PTP-S binds to the juxtamembrane region of the hepatocyte growth factor receptor Met. (1998) (36)
- Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction (2009) (36)
- Activation of the protein-tyrosine kinase associated with the bombesin receptor complex in small cell lung carcinomas. (1988) (35)
- Ligand-regulated Binding of FAP68 to the Hepatocyte Growth Factor Receptor* (2001) (35)
- Mouse immune interferon enhances fibronectin production of elicited macrophages. (1984) (35)
- PDGF-induced receptor phosphorylation and phosphoinositide hydrolysis are unaffected by protein kinase C activation in mouse Swiss 3T3 and human skin fibroblasts. (1986) (35)
- "Invasive-growth" signaling by the Met/HGF receptor: the hereditary renal carcinoma connection. (1997) (35)
- Genetic targeting of the kinase activity of the Met receptor in cancer cells (2007) (32)
- Feline STK gene expression in mammary carcinomas (2002) (32)
- An HGF–MSP chimera disassociates the trophic properties of scatter factors from their pro-invasive activity (2002) (31)
- MET-mediated resistance to EGFR inhibitors: an old liaison rooted in colorectal cancer stem cells. (2014) (29)
- Macrophage stimulating protein is a novel neurotrophic factor. (2001) (28)
- Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours (2019) (28)
- Regional mapping of the human hepatocyte growth factor (HGF)-scatter factor gene to chromosome 7q21.1. (1992) (27)
- Antigenic and immunogenic properties of membrane proteins solubilized by sodium desoxycholate, papain digestion or high ionic strength. (1975) (27)
- HGF and MET: From Brain Development to Neurological Disorders (2021) (27)
- Immunological detection of proteins phosphorylated at tyrosine in cells stimulated by growth factors or transformed by retroviral-oncogene-coded tyrosine kinases. (1986) (25)
- Sema 4 D induces angiogenesis through Met recruitment by Plexin B 1 (2005) (25)
- C-met inhibition blocks bone metastasis development induced by renal cancer stem cells (2016) (24)
- Solubilization of the receptor for the neuropeptide gastrin-releasing peptide (bombesin) with functional ligand binding properties. (1990) (23)
- Immunofluorescence localization of phosphotyrosine containing proteins in RSV-transformed mouse fibroblasts. (1984) (23)
- A Molecularly Annotated Model of Patient-Derived Colon Cancer Stem–Like Cells to Assess Genetic and Nongenetic Mechanisms of Resistance to Anti-EGFR Therapy (2017) (23)
- Cancer Genes (1996) (23)
- Plasma membrane fluidity and surface motility of mouse C-1300 neuroblastoma cells. (1973) (23)
- Whole exome sequencing identifies a germline MET mutation in two siblings with hereditary wild‐type RET medullary thyroid cancer (2018) (23)
- Inhibition of phosphotyrosine phosphatases reveals candidate substrates of the PDGF receptor kinase. (1989) (22)
- Biochemical and immunological properties of the human carcinoma-associated CAR-3 epitope defined by the monoclonal antibody AR-3. (1989) (22)
- MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients (2014) (22)
- Metastatic clones selected from an RSV‐induced mouse sarcoma share a common marker chromosome (1983) (22)
- MET/HGF Co-Targeting in Pancreatic Cancer: A Tool to Provide Insight into the Tumor/Stroma Crosstalk (2018) (22)
- Affinity chromatography purification of erythrocyte membrane proteins after selective labeling with trinitrobenzene sodium sulfonate. (1973) (22)
- Evidence for a membrane carrier molecule common to embryonal and tumour-specific antigenic determinants expressed by a mouse transplantable tumour. (1975) (21)
- Interleukin 1 induces an autocrine loop hepatocyte growth factor/c-Met in murine Kaposi-like spindle cells. (1996) (21)
- HGF controls branched morphogenesis in tubular glands. (1998) (21)
- A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors (2012) (21)
- Proteins phosphorylated on tyrosine as markers of human tumor cell lines (1987) (21)
- Identification of a 58,000 daltons phosphoprotein with tyrosine protein kinase activity in a murine lymphoma cell line. (1984) (21)
- Invasive growth: A two-way street for semaphorin signalling (2004) (21)
- Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors (2017) (20)
- Rebound Effects Caused by Withdrawal of MET Kinase Inhibitor Are Quenched by a MET Therapeutic Antibody. (2016) (20)
- Inhibition of ligand‐independent constitutive activation of the Met oncogenic receptor by the engineered chemically‐modified antibody DN30 (2015) (19)
- Cell delivery of Met docking site peptides inhibit angiogenesis and vascular tumor growth (2010) (19)
- Therapeutic dual inhibition of HER2 pathway for metastatic colorectal cancer (mCRC): The HERACLES trial. (2015) (19)
- Production of monoclonal antibodies for the immunohistochemical detection of gastric carcinomas. (1987) (18)
- Tankyrase inhibition impairs directional migration and invasion of lung cancer cells by affecting microtubule dynamics and polarity signals (2016) (18)
- Protein Tyrosine Kinases Associated with Human Malignancies a (1987) (17)
- Scatter factor receptors are key players in a unique multistep program leading to invasive growth. (1997) (17)
- Hepatocyte growth factor is a pleiotropic factor protecting epithelial cells from apoptosis. (1996) (17)
- Growth of Syngeneic Tumours in Unimmunized Newborn and Adult Hosts (1973) (17)
- The expression of LINE1‐MET chimeric transcript identifies a subgroup of aggressive breast cancers (2018) (17)
- Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation (2018) (17)
- Monoclonal antibodies against murine IFN-gamma abrogate in vivo tumor immunity against RSV-induced murine sarcomas. (1987) (16)
- Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence (2014) (16)
- Studies on the outer surface of normal and RSV-transformed BHK fibroblast plasma membrane. (1975) (15)
- Activation of the MET receptor attenuates doxorubicin‐induced cardiotoxicity in vivo and in vitro (2020) (15)
- A differentiation switch for genetically modified hepatocytes (2002) (15)
- Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor (2013) (15)
- A solid-state competitive binding radioimmunoassay for measurement of antigens solubilized from membranes. (1976) (15)
- Role of heterochromatin variation in the instability of a marker chromosome during tumor progression. (1985) (15)
- A receptor for bombesin with associated tyrosine kinase activity (1987) (14)
- Evidence for autocrine activation of a tyrosine kinase in a human gastric carcinoma cell line (1988) (14)
- Oncogenes, Cancer and Hemostasis (2007) (14)
- Cinnamamide analogs as inhibitors of protein tyrosine kinases. (1993) (14)
- Immunohistochemical study of IgA transepithelial transfer into digestive tract secretions in the mouse. (1973) (14)
- Metron factor‐1 prevents liver injury without promoting tumor growth and metastasis (2008) (14)
- Characterization of T lymphocytes mediating in vivo protection against RSV‐induced murine sarcomas (1983) (13)
- Comparison of blocked and non-blocked ricin-antibody immunotoxins against human gastric carcinoma and colorectal adenocarcinoma cell lines (2004) (13)
- Detection ofMET oncogene/hepatocyte growth factor receptor in lymph node metastases from head and neck squamous cell carcinomas (2006) (13)
- Tyrosine kinase and control of cell proliferation. (1990) (12)
- ABL proteins in Philadelphia‐positive acute leukaemias and chronic myelogenous leukaemia blast crises (1990) (12)
- Lipid characteristics of RSV-transformed Balb/c 3T3 cell lines with different spontaneous metastatic potentials (1989) (12)
- Mouse fibroblasts transformed by rous sarcoma virus express a virus‐specific non‐virion transplantation antigen (1981) (12)
- Erratum: Only a subset of met-activated pathways are required to sustain oncogene addiction (Science Signaling (2009) 2 (er11) (2009) (11)
- Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition (2021) (11)
- Cardiac concentric hypertrophy promoted by activated Met receptor is mitigated in vivo by inhibition of Erk1,2 signalling with Pimasertib. (2016) (11)
- Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: The HERACLES trial (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification). (2013) (11)
- A virus-induced non-virion antigen specific for transformation at the surface of RSV-transformed fibroblasts (1978) (11)
- Protein tyrosine phosphatase PTP-S binds to the juxtamembrane region of the hepatocyte growth factor receptor (1998) (11)
- Induction of resistance or enhancement to a transplantable murine plasmacytoma by transfer of non-immune leucocytes. (1976) (11)
- C-met activation is necessary but not sufficient for liver colonization by B16 murine melanoma cells (1998) (10)
- The Monoclonal Antibody-defined CAR-3 Antigen is a Serological Marker Associated with Pancreatic Carcinoma (1988) (10)
- Dual Constant Domain‐Fab: A novel strategy to improve half‐life and potency of a Met therapeutic antibody (2016) (10)
- Structure and functions of the HGF receptor (c-Met) (1995) (10)
- Cancer of Unknown Primary (CUP): genetic evidence for a novel nosological entity? A case report (2020) (10)
- A tumour-associated membrane antigen transiently expressed by normal cells during mitosis. (1974) (10)
- Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody‐“decoy” strategy (2018) (10)
- Hepatocyte Growth Factor/Scatter Factor Receptor (2004) (10)
- Detection ofphosphotyrosine-containing proteins inthedetergent- insoluble fraction ofRSV-transformed fibroblasts byazobenzene phosphonate antibodies (1984) (10)
- Regulation by EGF is maintained in an overexpressed chimeric EGFR/neu receptor tyrosine kinase (1990) (10)
- Differential requirement of the last C-terminal tail of Met receptor for cell transformation and invasiveness (2001) (9)
- Transformation-sensitive protein with molecular weight of 45,000 secreted by mouse fibroblasts. (1981) (9)
- Organization of cytoskeleton and fibronectin matrix in Rous sarcoma virus (RSV)-transformed fibroblast lines with different metastatic potential. (1985) (9)
- An ‘in‐cell trial’ to assess the efficacy of a monovalent anti‐MET antibody as monotherapy and in association with standard cytotoxics (2014) (9)
- Protein phosphorylation at tyrosine residues IN v‐abl transformed mouse lymphocytes and fibroblasts (1986) (9)
- Dissection of the antigenic determinants expressed on the cell surface of rsv‐transformed fibroblasts by monoclonal antibodies (1982) (9)
- MET Activation and Physical Dynamics of the Metastatic Process: The Paradigm of Cancers of Unknown Primary Origin (2017) (9)
- Monoclonal antibodies against the human epidermoid carcinoma A 431. (1985) (9)
- ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma. (2021) (8)
- Monoclonal antibodies to the collagen binding domain of human plasma fibronectin. (1984) (8)
- Expression of fibronectin receptor activity on immature hemopoietic cells (1986) (8)
- Effect of solubilized membrane antigens and tumour bearer serum on tumour growth in syngeneic hosts. (1974) (8)
- Experimental study on development and behaviour of the multinucleated giant cells "in vitro". (1971) (7)
- RON tyrosine kinase mutations in brain metastases from lung cancer (2018) (7)
- A Tyrosine Protein Kinase Activated by Bombesin in Normal Fibroblasts and Small Cell Carcinomas a (1988) (7)
- Plasma membrane proteins exposed on the outer surface of control and Rous sarcoma virus-transformed hamster fibroblasts. (1977) (7)
- Visualization of phosphotyrosine containing molecules within the detergent insoluble cell matrix of v-src transformed fibroblasts. (1984) (7)
- Ligand-independent tyrosine phosphorylation of the receptor encoded by the c-neu oncogene. (1991) (7)
- Cell surface changes during muscle differentiation in vitro: a study with the probe 2,4,6-trinitrobenzene sulphonate. (1979) (6)
- Constitutively activated neu oncoprotein tyrosine kinase interferes with growth factor‐induced signals for gene activation (1991) (6)
- Biochemical and immunological properties of the human carcinoma antigen car‐5 defined by the monoclonal antibody BD‐5 (1989) (6)
- Erratum: Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates (Cell 99:1 (71-80)) (2001) (6)
- Tumor‐specific and tumor‐associated membrane antigens of rous sarcoma virus transformed hamster fibroblasts (1978) (6)
- Relationship between Rous sarcoma virus-induced expression of membrane antigen and phenotypic transformation. (1979) (6)
- Two-Chains Tissue Plasminogen Activator Unifies Met and NMDA Receptor Signalling to Control Neuronal Survival (2021) (6)
- Signal transduction by growth factor receptors (1995) (5)
- Phosphoinositides are not phosphorylated by the very active tyrosine protein kinase from the murine lymphoma LSTRA. (1985) (5)
- Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs) (2022) (5)
- Molecular basis of the immunogenicity of cell surface tumor antigens. (1976) (5)
- Immunochemical purification of probe-labeled plasma membrane proteins: an approach to the molecular anatomy of the cell surface. (1978) (5)
- Involvement of sialic acids in the immunological specificity of plasma membrane glycoproteins. (1976) (5)
- Expression of the monoclonal antibody-defined CAR-3 epitope on neoplastic and preneoplastic lesions of the colon mucosa. (1987) (5)
- Target antigens for antibodies and complement at the cell surface of RSV-transformed fibroblasts. (1980) (5)
- Interaction between cellular and viral genes in the expression of the RSV‐induced transformation‐specific cell‐surface antigen VCSA (1980) (5)
- Amplification of the MET receptor to drive resistance to anti-EGFR therapies in colorectal cancer. (2013) (5)
- [Molecular markers study in pTNM of squamous carcinoma of the head and neck]. (2000) (4)
- The Long-Lasting Protective Effect of HGF in Cardiomyoblasts Exposed to Doxorubicin Requires a Positive Feed-Forward Loop Mediated by Erk1,2-Timp1-Stat3 (2020) (4)
- Immune complexes and circulating antibodies against autologous leukaemic cells in patients with acute leukaemias. (1982) (4)
- Cancer Therapy : Preclinical Genetic and Expression Analysis of MET , MACC 1 , and HGF in Metastatic Colorectal Cancer : Response to Met Inhibition in Patient Xenografts and Pathologic Correlations (2011) (4)
- Characterization of the detergent solubilized receptor for gastrin-releasing peptide (1990) (3)
- Production of a monoclonal antibody reacting with vimentin, a structural protein of intermediate filaments. (1986) (3)
- Effect of the growth conditions on the expression of cell-surface-associated platelet-derived growth factor receptors in mouse fibroblasts. (1988) (3)
- Identification of a glycoprotein expressed in cell-cell contacts by means of a monoclonal antibody (1986) (3)
- MET Exon 14 Skipping: A Case Study for the Detection of Genetic Variants in Cancer Driver Genes by Deep Learning (2021) (3)
- Scatter factor-dependent branching morphogenesis: structural and histological features. (2007) (3)
- MET∆14 promotes a ligand-dependent, AKT-driven invasive growth (2022) (2)
- Extracellular Targeting of Cell Signaling in Cancer: Strategies Directed at MET and RON Receptor Tyrosine Kinase Pathways, First Edition. Edited by James W. Janetka and Roseann M. Benson (2018) (2)
- Interferon-gamma inhibits cell replication, but not pp60src activity of RSV-transformed fibroblasts. (1987) (2)
- Growth factor receptors and class 1 oncogenes in cancer. (2009) (2)
- Kinetics of tyrosine phosphorylation and internalization of human EGF receptors overexpressed in NIH 3T3 fibroblasts. (1990) (2)
- Molecular Engineering Strategies Tailoring the Apoptotic Response to a MET Therapeutic Antibody (2020) (2)
- Small Molecule Therapeutics S 49076 Is a Novel Kinase Inhibitor of MET , AXL , and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab (2013) (2)
- A receptor-antibody hybrid hampering MET-driven metastatic spread (2021) (2)
- hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers (2022) (2)
- Engineering, Characterization, and Biological Evaluation of an Antibody Targeting the HGF Receptor (2021) (2)
- Blocked and not blocked whole-ricin-antibody immunotoxins: Intraperitoneal therapy of human tumour xenografted in nude mice (2004) (2)
- Interaction of Fibroblasts, Hemopoietic Cells and Platelets with Extracellular Matrix: Characterization and Role of a Common Cell Surface Glycoprotein a (1987) (2)
- Different cellular substrates of Abelson leukemia virus transforming protein kinase in murine fibroblasts and lymphocytes. (1985) (2)
- High Chemotactic Motility and Growth in Hard Agar of a Variant of RSV-Transformed Fibroblasts are Lost in Late Passages (1988) (2)
- The tyrosine kinase associated with the bombesin receptor complex: Evidences for autocrine activation in small cell lung carcinomas (1988) (2)
- Met-driven invasive growth involves transcriptional regulation of Arhgap 12 ONCOGENE (2015) (1)
- Bombesin receptor antagonists [corrected]. 1. Analogues with deleted, inverted or substituted amino acid residues. (1990) (1)
- Discovery and Function of the HGF/MET and the MSP/RON Kinase Signaling Pathways in Cancer (2018) (1)
- MET Oncogene Controls Invasive Growth by Coupling with NMDA Receptor (2022) (1)
- The hepatocyte growth factor receptor (MET): An unconventional transducer of mitogenic and motogenic signals (1996) (1)
- Multi-site phosphorylation of p190MET tyrosine kinase (1990) (1)
- Multinucleated giant cells in organ cultures of spleen (1969) (1)
- A chimeric antibody (MV-DN30) inhibiting (2014) (1)
- EXPRESSION OF MET MRNA AS PROGNOSTIC MARKER IN MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL DRUGS (2010) (1)
- Cell Surface Glycoproteins and Fibronectin Mediated Cell Adhesion (1982) (1)
- Erratum: Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice (Journal of Clinical Investigation (2010) 120:8 (2684-2698) DOI: 10.1172/JCI42118) (2011) (1)
- Mutated axon guidance gene PLXNB2 sustains growth and invasiveness of stem cells isolated from cancers of unknown primary (2023) (1)
- Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy (2022) (1)
- Correction for A Splicing Variant of the RON Transcript Induces Constitutive Tyrosine Kinase Activity and an Invasive Phenotype (1997) (1)
- Antigen-dependent mast cell differentiation in vitro. (1972) (1)
- Factor XII protects neurons from apoptosis by epidermal and hepatocyte growth factor receptor‐dependent mechanisms (2021) (1)
- Tankyrase inhibition impairs directional migration and invasion of lung cancer cells by affecting microtubule dynamics and polarity signals (2015) (1)
- Abstract A238: S 49076, a novel, potent, MET/FGFR/AXL kinase inhibitor with wide antitumor activity. (2011) (1)
- HGF/Met axis has anti-apoptotic and anti-autophagic function in hypoxic cardiac injury (2014) (1)
- Researchof HER family members in gastric carcinoma cells mediates resistance to MET inhibition (2010) (1)
- Enhancement of immunity against RSV-induced sarcomas by generation of hapten-reactive helper T lymphocytes. (1985) (1)
- Tumor and Stem Cell Biology Ror 1 Is a Pseudokinase That Is Crucial for Met-Driven Tumorigenesis (2011) (1)
- Carcinoma Metastases Activating Cell Motility and Invasion Oncogene in Human MET Novel Somatic Mutations of the Updated Version (2002) (1)
- The HGF receptor (Met) : transduction of signals for invasive cell growth (1995) (1)
- Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation (2023) (1)
- Correction: Magic-Factor 1, a Partial Agonist of Met, Induces Muscle Hypertrophy by Protecting Myogenic Progenitors from Apoptosis (2019) (0)
- Correction: hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers (2022) (0)
- High Expression of mRNA and Gene Amplification of Met In Myeloma Plasma Cells Characterize a More Aggressive Disease (2010) (0)
- Macrophage stimulating protein for the treatment of diseases of the nervous system (1998) (0)
- Deregulated tyrosine kinases detected in human tumors by means of antibodies against phosphotyrosine (1989) (0)
- Proteins phosphorylated at tyrosine residues in cells transformed by v-onc genes (1984) (0)
- [Immunochemical structure of the plasmatic membrane of transformed cells]. (1971) (0)
- Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor (2013) (0)
- Mono clonal antibodies against cell surface antigens of rous sarcoma virus transformed fibroblasts (1982) (0)
- Activation of the met oncogene tyrosine kinase by autophosphorylation (1990) (0)
- RON IS A HETERODIMERIC TYROSINE KINASE RECEPTOR ACTIVATED BY THE HGF HOMOLOG MSP / G. GAUDINO; A. FOLLENZI; L. NALDINI; C. COLLESI; M. SANTORO; (0)
- Identification and Localization of Phosphoproteins in v-onc Transformed Fibroblasts by Means of Phosphotyrosine Antibodies (1985) (0)
- Abstract 2358: miRNA-483-3p overexpression unleashes invasiveness of metastatic colorectal cancer by NDRG1 targeting and upregulation of the HER3-AKT axis (2021) (0)
- HGFR binding site high affinity and procedures for identification of antagonists thereof. (2009) (0)
- Met activation for cardioprotection against anthracycline cardiotoxicity (2015) (0)
- 1010 Control of invasive cell growth by receptors of the HGF family (1995) (0)
- [The distribution of motor plates in the mimic muscles of the dog (Canis familiaris L.)]. (1966) (0)
- Host and viral genes ionteracting at the tumor cell surface (1979) (0)
- MicroRNA 483-3p overexpression unleashes invasive growth of metastatic colorectal cancer via NDRG1 downregulation and ensuing activation of the ERBB3/AKT axis. (2023) (0)
- Solubilization of human bombesin/GRP receptors (1990) (0)
- Abstract 942: ErbB3 overexpression unleashed by miR-205 epigenetic silencing is a therapeutic target in glioblastoma (2021) (0)
- Abstract 3272: A Met receptor docking site peptide fused to cell-penetrating sequences acts as a powerful inhibitor of angiogenesis and vascular tumour growth (2011) (0)
- L11.02 COLORECTAL CANCER XENOPATIENTS: A PRECLINICAL PLATFORM FOR PRECISION MEDICINE (2013) (0)
- Agnostos precision medicine project in patients (PTS) with cancer of unknown primary (CUP) (2016) (0)
- The Receptor for the Hepatocyte Growth Factor-Scatter Factor: Ligand-Dependent and Phosphorylation-Dependent Regulation of Kinase Activity (1992) (0)
- Affinity constant of anti-DNP secretory IgA. (1970) (0)
- Proteins phosphorylated on tyrosine as markers of human malignancies (1987) (0)
- The activation of the cellular oncogene c-abl in chronic myelogenous and acute lymphoblastic leukemias (1987) (0)
- Abstract C92: MET amplification and overexpression sustain resistance and drive drug dependency to the DN30Fab antibody in MET-addicted cells. (2013) (0)
- Abstract 622: Gastric cancer in the age of targeted agents: identification and validation of novel therapeutic strategies through the generation of a patient-derived xenografts platform (2016) (0)
- Deregulation of the tyrosine kinase associated with the bombesin receptor in small cell lung carcinomas (1987) (0)
- Magic F1, a dimerized c-met binding domain, induces muscle hypertrophy by protecting from apoptosis myogenic progenitors (2006) (0)
- Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy (2018) (0)
- Identification and partial characterization of five major membrane glycoproteins of BHK fibroblasts (1980) (0)
- Abstract 2871: Hypermetastatic stem-like cells from 'cancer of unknown primary' (CUP) model multi-organ dissemination and unveil liability to MEK inhibition (2021) (0)
- MET inhibitors to enhance the efficacy of radiotherapy (2011) (0)
- Altered regulation of receptor associated-tyrosine kinases in human tumors (1989) (0)
- A single amino acid substitution turns Scatter Factor into a potent inhibitor of tumor dissemination (2007) (0)
- Primary humoral immune response against tumor membrane antigens and foreign antigens by plasma cell tumor bearer mice. (1977) (0)
- HGF (Hepatocyte Growth Factor)/MET System (2003) (0)
- S57Agnostos precision medicine project: a multicenter clinical and translational initiative in patients (PTS) with cancer of unknown primary (CUP) (2016) (0)
- Immunochemistry of the Cell Membrane: Advanced Course, Ravello, July 1975: Proceedings (1977) (0)
- Targeting tumor growth, vascularization and metastasis by HGF antagonists (2003) (0)
- Growth Factor Receptor (2020) (0)
- 1999 Referees (1999) (0)
- A putative tyrosine kinase receptor encoded by the protooncogene (1990) (0)
- A SPLICING VARIANT OF THE RON TRANSCRIPT INDUCES CONSTITUTIVE TYROSINE KINASE ACTIVITY AND INVASIVE PHENOTYPE / C. COLLESI; (0)
- The PSI Domain of the MET Oncogene Encodes a Functional Disulfide Isomerase Essential for the Maturation of the Receptor Precursor (2022) (0)
- RSV transformed fibroblasts and monocytes share peculiar adhesion sites (1986) (0)
- Abstract 3606: Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence (2015) (0)
- SCATTER FACTORS IN TUMOR PROGRESSION (2006) (0)
- Phosphotyrosine antibodies as probes for activated oncogene products endowed with tyrosine kinase activity. (1991) (0)
- The HGF receptor, a targettable regulator of invasive growth (2007) (0)
- Contents, Vol. 44, 1976 (1976) (0)
- Gene expression profiles for predicting treatment response in patients with chronic hepatitis C: preliminary analysis (2007) (0)
- Ionizing radiation fosters cancer invasion through transcriptional up-regulation of the MET oncogene (2008) (0)
- moto genesis peptide antagonists of cellular mitogenesis and, and their therapeutic use (1997) (0)
- Abstract B17: Xenospheres: a comprehensive patient-derived in vitro model to study response and resistance to targeted therapies in metastatic colorectal cancer (2016) (0)
- Structure, Biosynthesis and Biochemical Properties of the HGF/SF Receptor (1993) (0)
- Structural comparison of plasmatic membranes of 3t3 and sv 3t3 fibroblasts surface protein study (1973) (0)
- Control of Invasive Cell Growth by the Met Family Oncogenes (1996) (0)
- Hepatocyte growth factor/met system (2003) (0)
- HGF-mimic antibody administration to counteract doxorubicin cardiotoxicity (2018) (0)
- Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours (2019) (0)
- Abstract 3398: Double-faced Sema3E-PlexinD1 signaling inhibits tumor growth but promotes metastatic spreading (2010) (0)
- Abstract 1387: MET inhibition radiosensitizes KRAS-mutant rectal cancer (2021) (0)
- Proteins phosphorylated on tyrosine in human breast cancer (1990) (0)
- Cancer Therapy : Preclinical InhibitionofMEKandPI 3 K / mTORSuppressesTumorGrowth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas (2012) (0)
- The HGF/SF receptor kinase: structure and function (1993) (0)
- Met mRNA value predicts outcome in multiple myeloma patients (2010) (0)
- Stem-like cells from Cancer of Unknown Primary are endowed with distinctive hypermetastatic properties and unveil liability to MEK inhibition (2020) (0)
- Truncated forms of hepatocyte growth factor (HGF) receptor (1992) (0)
- [579] MICROARRAYS ANALYSIS FOR PREDICTING TREATMENT RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS C: PRELIMINARY DATA (2007) (0)
- Signal transducers as molecular targets for cancer therapy (1997) (0)
- [Tyrosine-phosphorylated proteins in human breast carcinoma]. (1990) (0)
- A new 'blocked' immunotoxin (1987) (0)
- Expression of the MET Oncogene in Human Tumors (1992) (0)
- INTEGRATED SYSTEMS AND TECHNOLOGIES 3206 Application of Raman Spectroscopy to Identify Microcalcifications and Underlying Breast Lesions at Stereotactic Core Needle Biopsy (2013) (0)
- 312 MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors (2010) (0)
- [Simple method for culture of lymphatic organs]. (1970) (0)
- Human Cancer Biology MiR-1 DownregulationCooperateswithMACC 1 inPromoting MET Overexpression in Human Colon Cancer (2012) (0)
- HGF-DERIVED RECOMBINANT PROTEIN M.A.G.I.C. F1: A NOVEL APPROACH TO INDUCE MUSCULAR HYPERTROPHY (2006) (0)
- HGFR binding site with high affinity, and methods for identification of antagonists thereof (2009) (0)
- 759 Xenospheres – a Preclinical Model of Tumor-initiating Cells to Study the Response to Targeted Therapies in Metastatic Colorectal Cancer (2012) (0)
- Markofagstimulerende protein for the treatment of diseases of the central nervous system (1998) (0)
- 928: Met signaling sustains glioblastoma stem cells radioresistance (2014) (0)
- In vitro kinetics of embryonic spleen cells. (1971) (0)
- Abstracts from the EACR seed and soil: in vivo models of metastasis conference (2018) (0)
- Met-Dependent Invasive Growth by Notch Negative Feedback Regulation of (2005) (0)
- Abstract 631: Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody (2011) (0)
- 265 The MET oncogene: physiology and pathology of invasive growth (2009) (0)
- ProteinApoptosis Enhancement by the HIV-1 Nef (2000) (0)
- Subject Index, Vol. 44, 1976 (1976) (0)
- Coagulation Factor XII protects neurons from apoptosis by triggering a crosstalk between HGFR/c-Met and EGFR/ErbB1 signaling pathways (2020) (0)
- Abstract 828: Targeting theMEToncogene by concomitant inhibition of receptor and ligand by an antibody-‘decoy' strategy (2018) (0)
- Tumor and Stem Cell Biology Ron Kinase Transphosphorylation Sustains MET Oncogene Addiction (2011) (0)
- Monoclonal antibodies against murine interferon-y (IFN-y) (1984) (0)
- Table of Contents (1984) (0)
- p145, a Protein withAssociated Tyrosine KinaseActivity ina HumanGastric Carcinoma CellLine (1988) (0)
- Biochemical and Immunological Properties of the Human Carcinoma-associated CAR-3 Epitope Defined by the Monoclonal Antibody AR-31 (1989) (0)
- The inhibition of c-MET reduces bone metastases induced by renal cancer stem cells (2015) (0)
- SP-0510: Targeting the MET oncogene to radiosensitize cancer stem cells (2013) (0)
- Oncogenic potential of MET SEMA mutations affecting brain metastases from NSCLC is sustained by their microrheological features (2017) (0)
- Detection of deregulated tyrosine-kinases in experimental and human metastatic tumors. (1988) (0)
- Modulation of fibronectin mediated cell adhesion by proteolytic cleavage of membrane proteins (1981) (0)
- A genome-wide trap screening procedure for transcriptionally responsive genes (2001) (0)
- A receptor-antibody hybrid hampering MET-driven metastatic spread (2021) (0)
- Morphological and biochemical changes of rat prostate organ cultures and their reaction to prostate extracts. (1971) (0)
- Mapping of the c-met oncogene amplicon in a human gastric carcinoma cell line (1991) (0)
- Derivation and charaterization of cancer initialling cells representative of metastatic colorectal cancer genetic heterogeneity (2015) (0)
- [Action of phytohemagglutinin on the embryonal spleen in organotypic culture]. (1967) (0)
- Mono clonal antibodies to human fibronectin (1980) (0)
- Met Over-Expression Is a Prognostic Factor for Myeloma Patients Treated with Novel Agents (2009) (0)
- Hepatocyte growth factor links osteoclast-osteoblast actyvity through an autocrine-paracrine signaling (2006) (0)
- Abstract 633: Target therapy of glioblastoma by gene transfer of a monovalent antibody against the MET oncogene (2011) (0)
- MET genetic lesions in NSCLC are functional markers of early hematogenous spreading and radioresistance (2015) (0)
- Correction: hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers (2022) (0)
- [Structure of the cell membrane and tumor antigens of the cell surface of BHK fibroblasts transformed by RSV (proceedings)]. (1977) (0)
- hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers (2022) (0)
- Stympade of the former hepatocytvaextfaktorreceptor (1993) (0)
- 365 Cell delivery of the Met docking site peptide inhibits angiogenesis and vascular tumour growth (2010) (0)
- The Bombesin Receptor Complex and Cell Growth: Physiology and Pathology (1990) (0)
- Targeted anticancer therapy by a recombinant monovalent antibody against the MET oncogene (2011) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Paolo Maria Comoglio?
Paolo Maria Comoglio is affiliated with the following schools:
